Jason E Galloway1,2, Andrea M Holderbaum1,2, Namrata Arya1,2, Suohui Zhang1,2, Michael S Bodnar1,2, Ruthann Norman3, William E Carson3, Lianbo Yu4, Kari L Kendra5, Christin E Burd1,2. 1. Department of Molecular Genetics, The Ohio State University College of Arts and Sciences, Columbus, OH 43210. 2. Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH 43210. 3. Department of Surgery, Division of Surgical Oncology, The Ohio State University College of Medicine, Columbus, OH 43210. 4. Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH 43210. 5. Medical Oncology Division, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH 43210.
Abstract
BACKGROUND: The impact of biologic aging on immune checkpoint inhibitor (ICI) toxicity and efficacy is underexplored in metastatic melanoma (MM). In peripheral blood T-lymphocytes (PBTLs), biologic aging is characterized by changes in T-cell composition and cellular senescence. Whether indicators of PBTL biologic aging vary in MM patients or can be used to predict premature ICI discontinuation (pID) is unknown. METHODS: We prospectively collected PBTLs from 117 cancer-free controls and 46 MM patients scheduled to begin pembrolizumab or nivolumab monotherapy. 74 mRNAs indicative of T-cell subsets, activation, co-stimuation/inhibition and cellular senescence were measured by Nanostring. Relationships between each mRNA and chronologic age were assessed in patients and controls. Candidate biomarkers were identified by calculating the hazard ratio (HR) for pID in patients divided into low and high groups based on log-transformed mRNA levels or the magnitude by which each mRNA measurement deviated from the control trend (Δage). Area under the curve (AUC) analyses explored the ability of each biomarker to discriminate between patients with and without pID at 6 months and 1 year. RESULTS: Fifteen mRNAs correlated with chronologic age in controls, including markers of T-cell subsets, differentiation, cytokine production and co-stimulation/inhibition. None of these mRNAs remained correlated with age in patients. Median follow-up was 94.8 (1.6-195.7) weeks and 35 of 46 patients discontinued therapy (23 progression, 7 toxicity, 5 comorbidity/patient preference). Elevated pre-therapy CD8A (HR 2.2[1.1-4.9]), CD45RB (HR 2.9[1.4-5.8]) and TNFRSF14 (HR 2.2[1.1-4.5]) levels predicted pID independent of Δage-correction. CD3ε, CD27 and FOXO1 predicted pID only after Δage-correction (HR 2.5[1.3-5.1]; 3.7[1.8-7.8]; 2.1[1.1-4.3]). AUC analysis identified Δage-CD3ε and -CD27 as candidate predictors of pID (AUC=0.73; 0.75). CONCLUSIONS: Correlations between transcriptional markers of PBTL composition and chronologic age are disrupted in MM. Correcting for normal, age-related trends in biomarker expression unveils new biomarker candidates predictive of ICI outcomes.
BACKGROUND: The impact of biologic aging on immune checkpoint inhibitor (ICI) toxicity and efficacy is underexplored in metastatic melanoma (MM). In peripheral blood T-lymphocytes (PBTLs), biologic aging is characterized by changes in T-cell composition and cellular senescence. Whether indicators of PBTL biologic aging vary in MM patients or can be used to predict premature ICI discontinuation (pID) is unknown. METHODS: We prospectively collected PBTLs from 117 cancer-free controls and 46 MM patients scheduled to begin pembrolizumab or nivolumab monotherapy. 74 mRNAs indicative of T-cell subsets, activation, co-stimuation/inhibition and cellular senescence were measured by Nanostring. Relationships between each mRNA and chronologic age were assessed in patients and controls. Candidate biomarkers were identified by calculating the hazard ratio (HR) for pID in patients divided into low and high groups based on log-transformed mRNA levels or the magnitude by which each mRNA measurement deviated from the control trend (Δage). Area under the curve (AUC) analyses explored the ability of each biomarker to discriminate between patients with and without pID at 6 months and 1 year. RESULTS: Fifteen mRNAs correlated with chronologic age in controls, including markers of T-cell subsets, differentiation, cytokine production and co-stimulation/inhibition. None of these mRNAs remained correlated with age in patients. Median follow-up was 94.8 (1.6-195.7) weeks and 35 of 46 patients discontinued therapy (23 progression, 7 toxicity, 5 comorbidity/patient preference). Elevated pre-therapy CD8A (HR 2.2[1.1-4.9]), CD45RB (HR 2.9[1.4-5.8]) and TNFRSF14 (HR 2.2[1.1-4.5]) levels predicted pID independent of Δage-correction. CD3ε, CD27 and FOXO1 predicted pID only after Δage-correction (HR 2.5[1.3-5.1]; 3.7[1.8-7.8]; 2.1[1.1-4.3]). AUC analysis identified Δage-CD3ε and -CD27 as candidate predictors of pID (AUC=0.73; 0.75). CONCLUSIONS: Correlations between transcriptional markers of PBTL composition and chronologic age are disrupted in MM. Correcting for normal, age-related trends in biomarker expression unveils new biomarker candidates predictive of ICI outcomes.
Authors: Christin E Burd; Juan Peng; Bryon F Laskowski; Jennifer L Hollyfield; Suohui Zhang; Paolo Fadda; Lianbo Yu; Rebecca R Andridge; Janice K Kiecolt-Glaser Journal: J Gerontol A Biol Sci Med Sci Date: 2020-11-13 Impact factor: 6.053
Authors: Julie A E Nelson; Janakiraman Krishnamurthy; Prema Menezes; Yan Liu; Michael G Hudgens; Norman E Sharpless; Joseph J Eron Journal: Aging Cell Date: 2012-10 Impact factor: 9.304
Authors: Yan Liu; Hanna K Sanoff; Hyunsoon Cho; Christin E Burd; Chad Torrice; Joseph G Ibrahim; Nancy E Thomas; Norman E Sharpless Journal: Aging Cell Date: 2009-05-22 Impact factor: 9.304
Authors: Curtis H Kugel; Stephen M Douglass; Marie R Webster; Amanpreet Kaur; Qin Liu; Xiangfan Yin; Sarah A Weiss; Farbod Darvishian; Rami N Al-Rohil; Abibatou Ndoye; Reeti Behera; Gretchen M Alicea; Brett L Ecker; Mitchell Fane; Michael J Allegrezza; Nikolaos Svoronos; Vinit Kumar; Daniel Y Wang; Rajasekharan Somasundaram; Siwen Hu-Lieskovan; Alpaslan Ozgun; Meenhard Herlyn; Jose R Conejo-Garcia; Dmitry Gabrilovich; Erica L Stone; Theodore S Nowicki; Jeffrey Sosman; Rajat Rai; Matteo S Carlino; Georgina V Long; Richard Marais; Antoni Ribas; Zeynep Eroglu; Michael A Davies; Bastian Schilling; Dirk Schadendorf; Wei Xu; Ravi K Amaravadi; Alexander M Menzies; Jennifer L McQuade; Douglas B Johnson; Iman Osman; Ashani T Weeraratna Journal: Clin Cancer Res Date: 2018-06-13 Impact factor: 12.531
Authors: William A Wood; Janakiraman Krishnamurthy; Natalia Mitin; Chad Torrice; Joel S Parker; Anna C Snavely; Thomas C Shea; Jonathan S Serody; Norman E Sharpless Journal: EBioMedicine Date: 2016-08-21 Impact factor: 8.143